Oxford Biomedica (LON:OXB) Reaches New 52-Week High – What’s Next?

Oxford Biomedica plc (LON:OXB) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as GBX 693 and last traded at GBX 691, with a volume of 127693 shares traded. The stock had previously closed at GBX 663.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 451 price objective on shares of Oxford Biomedica in a report on Tuesday, October 7th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 558.

Oxford Biomedica Stock Up 2.3%

The business has a 50-day moving average price of GBX 621.67 and a two-hundred day moving average price of GBX 539.07. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. The firm has a market cap of £817.25 million, a PE ratio of -18.72 and a beta of 1.09.

Insider Buying and Selling

In other news, insider Heather Preston acquired 6,175 shares of the company’s stock in a transaction on Monday, October 20th. The shares were bought at an average cost of GBX 593 per share, with a total value of £36,617.75. 34.83% of the stock is owned by insiders.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.